Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M93,366Revenue (TTM) $M16,571Net Margin (%)33.7Altman Z-Score11.7
Enterprise Value $M91,478EPS (TTM) $2.2Operating Margin %43.5Piotroski F-Score5
P/E(ttm)17.1Beneish M-Score-2.6Pre-tax Margin (%)42.5Higher ROA y-yN
Price/Book15.510-y EBITDA Growth Rate %19.2Quick Ratio0.9Cash flow > EarningsY
Price/Sales5.85-y EBITDA Growth Rate %17.9Current Ratio1.2Lower Leverage y-yY
Price/Free Cash Flow16.6y-y EBITDA Growth Rate %-4.6ROA % (ttm)43.1Higher Current Ratio y-yN
Dividend Yield %3.9PEG0.9ROE % (ttm)88.7Less Shares Outstanding y-yY
Payout Ratio %63.0Shares Outstanding M2,600ROIC % (ttm)142Gross Margin Increase y-yN

Gurus Latest Trades with NVO

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVOKen Fisher 2016-09-30 Reduce-0.01%$41.59 - $57.05
($49.58)
$ 34.97-29%Reduce -0.48%10,910,669
NVOMario Gabelli 2016-09-30 Sold Out $41.59 - $57.05
($49.58)
$ 34.97-29%Sold Out0
NVOKen Fisher 2016-06-30 Reduce-0.02%$50.91 - $57.51
($54.83)
$ 34.97-36%Reduce -1.93%10,963,094
NVORuane Cunniff 2016-06-30 Reduce$50.91 - $57.51
($54.83)
$ 34.97-36%Reduce -3.45%94,165
NVOMario Gabelli 2016-06-30 Reduce$50.91 - $57.51
($54.83)
$ 34.97-36%Reduce -0.79%6,176
NVOKen Fisher 2016-03-31 Reduce-0.03%$46.58 - $58.08
($53.57)
$ 34.97-35%Reduce -2.35%11,178,809
NVORuane Cunniff 2016-03-31 Add0.01%$46.58 - $58.08
($53.57)
$ 34.97-35%Add 19.93%97,525
NVOMario Gabelli 2016-03-31 Add$46.58 - $58.08
($53.57)
$ 34.97-35%Add 0.24%6,225
NVOKen Fisher 2015-12-31 Reduce-0.02%$52.93 - $58.77
($55.36)
$ 34.97-37%Reduce -1.76%11,447,413
NVOMario Gabelli 2015-12-31 Add$52.93 - $58.77
($55.38)
$ 34.97-37%Add 0.65%6,210
NVOKen Fisher 2015-09-30 Reduce-0.07%$52.8 - $60.23
($56.62)
$ 34.97-38%Reduce -5.23%11,652,268
NVORuane Cunniff 2015-09-30 Reduce$52.8 - $60.23
($56.62)
$ 34.97-38%Reduce -0.59%81,320
NVOMario Gabelli 2015-09-30 Reduce$52.8 - $60.23
($56.62)
$ 34.97-38%Reduce -5.73%6,170
NVOKen Fisher 2015-06-30 Reduce-0.04%$53.39 - $58.02
($56.17)
$ 34.97-38%Reduce -2.88%12,295,864
NVORuane Cunniff 2015-06-30 Reduce$53.39 - $58.02
($56.17)
$ 34.97-38%Reduce -0.30%81,800
NVOMario Gabelli 2015-06-30 Reduce$53.39 - $58.02
($56.17)
$ 34.97-38%Reduce -2.31%6,545
NVOKen Fisher 2015-03-31 Reduce-0.03%$41.9 - $54.68
($46.05)
$ 34.97-24%Reduce -2.91%12,660,235
NVORuane Cunniff 2015-03-31 Reduce$41.9 - $54.68
($46.05)
$ 34.97-24%Reduce -0.17%82,050
NVOMario Gabelli 2015-03-31 Reduce$41.9 - $54.68
($46.05)
$ 34.97-24%Reduce -0.30%6,700
NVORuane Cunniff 2014-09-30 Reduce-0.02%$43.9 - $49.03
($46)
$ 34.97-24%Reduce -52.87%75,642
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVO is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NVO: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about NVO:

    News about NVO:

    Articles On GuruFocus.com
    Gurus Invest in Undervalued Biotech Stocks Nov 25 2016 
    23 Questions With Thomas Macpherson of Nintai Partners Nov 21 2016 
    Graham's 4 Vital Elements Nov 10 2016 
    World Leader in Diabetes Medication Hits 2-Year Low Nov 07 2016 
    Buy Health Care Now? It All Depends on the Election Nov 07 2016 
    Eaton Vance Worldwide Health Sciences Fund 3rd Quarter Commentary Oct 26 2016 
    Novo Nordisk: Jim Simons' Largest Holding Oct 24 2016 
    Stocks With High Yield: Oracle, Cal-Maine, Infosys Jul 28 2016 
    My Favorite Health Care Stocks Jul 12 2016 
    Nintai Charitable Trust's 2nd-Quarter Results Jul 01 2016 

    More From Other Websites
    Moody's Assigns Provisional Ratings to Eight CMBS Classes of CSMC 2016-NXSR Dec 08 2016
    10 Largest Hedge Funds in The World And Their Favorite Stock Picks Dec 08 2016
    BUZZ-European Pharma: UBS shuffles recommendations Dec 07 2016
    Business Watch Dec 07 2016
    [$$] Business Watch Dec 06 2016
    Novo Nordisk Pledges to Limit Price Increases in U.S. for Its Drugs Dec 06 2016
    Novo Nordisk Files Regulatory Application for Semaglutide Dec 06 2016
    A second major drugmaker says it will cap price increases Dec 06 2016
    A second major drugmaker just committed to limiting price increases Dec 05 2016
    Novo's Pricing Pledge Is a Sign of More to Come Dec 05 2016
    Novo Nordisk Files for Regulatory Approval of Once-Weekly Semaglutide with the FDA for the Treatment... Dec 05 2016
    Novo Nordisk A/S (ADR) (NVO)Hedge Funds Are Snapping Up Dec 05 2016
    These drug and medical device companies made $5.6 million in nonresearch payments to Washington... Dec 01 2016
    Novo Nordisk A/S: Tresiba® demonstrates a safe cardiovascular profile and reduces the risk of... Dec 01 2016
    [$$] Novo Nordisk shares rally on insulin trial results Nov 30 2016
    Novo Nordisk's Tresiba Shows Safe Cardiovascular Profile Nov 30 2016
    Novo's New Insulin Reduces Risk of Low Blood Sugar, Study Shows Nov 29 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)